Detalhe da pesquisa
1.
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
J Pharmacol Exp Ther
; 380(3): 210-219, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35031585
2.
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
Cell Mol Life Sci
; 73(4): 883-900, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26346493
3.
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
J Cell Sci
; 127(Pt 4): 788-800, 2014 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24363449
4.
A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3ß to phosphorylate cyclin D1 at Thr(286), not Thr(288).
Biochem J
; 457(1): 43-56, 2014 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24134204
5.
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Breast Cancer Res
; 16(1): R12, 2014 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24457069
6.
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Breast Cancer Res
; 16(5): 430, 2014 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25212826
7.
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
Biochem J
; 452(3): 499-508, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23581296
8.
Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis.
Biochem J
; 444(1): 141-51, 2012 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22428559
9.
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
Neuro Oncol
; 25(1): 146-156, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35639513
10.
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Target Oncol
; 18(2): 269-285, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36826464
11.
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Lancet Haematol
; 10(1): e46-e58, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370742
12.
Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models.
J Med Chem
; 65(4): 3306-3331, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133824
13.
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
Biochem Soc Trans
; 39(2): 456-9, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21428919
14.
FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
Blood Adv
; 5(9): 2385-2390, 2021 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33944896
15.
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST.
Clin Cancer Res
; 26(14): 3751-3759, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32220888
16.
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Sci Transl Med
; 12(541)2020 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32350132
17.
AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
Clin Cancer Res
; 25(5): 1574-1587, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30559170
18.
Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
Eur J Cancer
; 44(2): 310-7, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18077151
19.
Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies.
J Chromatogr B Analyt Technol Biomed Life Sci
; 863(1): 19-25, 2008 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18221921
20.
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
J Med Chem
; 61(22): 9889-9907, 2018 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30346772